Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 6/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 3/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GPR183 | P32249 | 1/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17724134 | 0.88 | PDE1B (0.46) | PDE1BKDM4ETDP1DRD4GRM2 | |
| SCHEMBL23939259 | 0.84 | KDM4E (0.47) | PDE1BKDM4ETDP1SIGMAR1GRM2 | |
| SCHEMBL19532828 | 0.81 | SIGMAR1 (0.46) | PDE1BKDM4ETDP1DRD4SIGMAR1 | |
| SCHEMBL20605214 | 0.81 | KDM4E (0.45) | PDE1BKDM4ETDP1GRM2HTT | |
| SCHEMBL19532826 | 0.78 | SIGMAR1 (0.46) | PDE1BKDM4ETDP1DRD4SIGMAR1 | |
| SCHEMBL12383 | 0.77 | ALDH1A1 (0.55) | KDM4ETDP1SIGMAR1HTTCYP2A13 | |
| SCHEMBL17724130 | 0.75 | HRH3 (0.54) | KDM4EHTTCYP2A13ALDH1A1GPR183 | |
| SCHEMBL24746120 | 0.74 | ALDH1A1 (0.72) | KDM4EDRD4TMEM97SIGMAR1HTT | |
| SCHEMBL4480082 | 0.73 | KDM4E (0.56) | PDE1BKDM4ETDP1GRM2HTT | |
| SCHEMBL4480084 | 0.73 | KDM4E (0.56) | PDE1BKDM4ETDP1GRM2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3643709-B1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2021-10-20 | — | — | EP | disclosed |
| EP-3643709-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Kangpu Biopharmaceuticals, Ltd. (CN) | 2020-04-29 | — | — | EP | disclosed |
| US-20170313676-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| EP-3214081-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Kangpu Biopharmaceuticals, Ltd. (CN) | 2017-09-06 | — | — | EP | disclosed |
| WO-2016065980-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 康朴生物医药技术（上海）有限公司 | 2016-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313676-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | IL2, IL1B, IL5 | PDE1B 2668/4885KDM4E 4086/4885TDP1 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.